Next Article in Journal
Biologics in Dermatology
Next Article in Special Issue
Natural Products as a Source for New Anti-Inflammatory and Analgesic Compounds through the Inhibition of Purinergic P2X Receptors
Previous Article in Journal
Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors
Article Menu

Export Article

Open AccessCommunication
Pharmaceuticals 2013, 6(4), 546-556; doi:10.3390/ph6040546

An Allosteric Modulator of the Adenosine A1 Receptor Improves Cardiac Function Following Ischaemia in Murine Isolated Hearts

School of Medical Sciences, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
Author to whom correspondence should be addressed.
Received: 4 March 2013 / Revised: 26 March 2013 / Accepted: 1 April 2013 / Published: 12 April 2013
(This article belongs to the Special Issue Purine and Its Derivatives)
View Full-Text   |   Download PDF [517 KB, uploaded 12 April 2013]   |  


The effect of an allosteric modulator of the adenosine A1 receptors was investigated using an ischaemia-reperfusion protocol in murine isolated hearts. Isolated hearts were perfused with Kreb-Henseleit solution gassed with carbogen gas (95% O2 and 5% CO2) in Langendorff mode and electrically paced at 480 bpm. Following 20 min equilibration and 20 min global normothermic ischaemia, the allosteric modulator VCP333 (1 μM) or the adenosine A1 receptor partial agonist VCP102 (10 μM) were infused after 5 min of reperfusion for 15 min. Upon termination of the drug treatment, reperfusion continued for a further 40 min. At the end of 60 min reperfusion, treatment with VCP333 or VCP102 improved the recovery of the left ventricular developed pressure when compared to control group responses (p < 0.05). Neither compound affected end diastolic pressure, coronary flow rates or dP/dtmax values when compared to control tissues during reperfusion (p > 0.05). The infusion of VCP102 or VCP333 during reperfusion reduced cardiac troponin I efflux to 6.7% and 25% respectively of control heart efflux (p < 0.05). This data indicates that the allosteric modulator of the adenosine A1 receptor (VCP333) has similar characteristics to the adenosine receptor partial agonist VCP102 as it improves cardiac function and reduces myocardial cell death following an ischaemic episode. View Full-Text
Keywords: allosteric modulator; adenosine A1 receptor; cardioprotection; heart allosteric modulator; adenosine A1 receptor; cardioprotection; heart

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Butcher, A.; Scammells, P.J.; White, P.J.; Devine, S.M.; Rose'Meyer, R.B. An Allosteric Modulator of the Adenosine A1 Receptor Improves Cardiac Function Following Ischaemia in Murine Isolated Hearts. Pharmaceuticals 2013, 6, 546-556.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top